Literature DB >> 31999897

Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis.

Alessandra Mingione1, Michele Dei Cas2, Fabiola Bonezzi3, Anna Caretti1, Marco Piccoli3, Luigi Anastasia4, Riccardo Ghidoni1, Rita Paroni2, Paola Signorelli5.   

Abstract

BACKGROUND/AIMS: Cystic Fibrosis (CF) is an inherited disease associated with a variety of mutations affecting the CFTR gene. A deletion of phenylalanine 508 (F508) affects more than 70% of patients and results in unfolded proteins accumulation, originating a proteinopathy responsible for inflammation, impaired trafficking, altered metabolism, cholesterol and lipids accumulation, impaired autophagy at the cellular level. Lung inflammation has been extensively related to the accumulation of the lipotoxin ceramide. We recently proved that inhibition of ceramide synthesis by Myriocin reduces inflammation and ameliorates the defence response against pathogens infection, which is downregulated in CF. Here, we aim at demonstrating the mechanisms of Myriocin therapeutic effects in Cystic Fibrosis broncho-epithelial cells.
METHODS: The effect of Myriocin treatment, on F508-CFTR bronchial epithelial cell line IB3-1 cells, was studied by evaluating the expression of key proteins and genes involved in autophagy and lipid metabolism, by western blotting and real time PCR. Moreover, the amount of glycerol-phospholipids, triglycerides, and cholesterols, sphingomyelins and ceramides were measured in treated and untreated cells by LC-MS. Finally, Sptlc1 was transiently silenced and the effect on ceramide content, autophagy and transcriptional activities was evaluated as above mentioned.
RESULTS: We demonstrate that Myriocin tightly regulates metabolic function and cell resilience to stress. Myriocin moves a transcriptional program that activates TFEB, major lipid metabolism and autophagy regulator, and FOXOs, central lipid metabolism and anti-inflammatory/anti-oxidant regulators. The activity of these transcriptional factors is associated with the induction of PPARs nuclear receptors activity, whose targets are genes involved in lipid transport compartmentalization and oxidation. Transient silencing of SPTCL1 recapitulates the effects induced by Myriocin.
CONCLUSION: Cystic Fibrosis bronchial epithelia accumulate lipids, exacerbating inflammation. Myriocin administration: i) activates the transcriptions of genes involved in enhancing autophagy-mediated stress clearance; ii) reduces the content of several lipid species and, at the same time, iii) enhances mitochondrial lipid oxidation. Silencing the expression of Sptlc1 reproduces Myriocin induced autophagy and transcriptional activities, demonstrating that the inhibition of sphingolipid synthesis drives a transcriptional program aimed at addressing cell metabolism towards lipid oxidation and at exploiting autophagy mediated clearance of stress. We speculate that regulating sphingolipid de novo synthesis can relieve from chronic inflammation, improving energy supply and anti-oxidant responses, indicating an innovative therapeutic strategy for CF. © Copyright by the Author(s). Published by Cell Physiol Biochem Press.

Entities:  

Keywords:  Lipid metabolism; Ceramide; Proteinopathy; Autophagy; Cystic Fibrosis

Mesh:

Substances:

Year:  2020        PMID: 31999897     DOI: 10.33594/000000208

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  7 in total

1.  An Innovative Lipidomic Workflow to Investigate the Lipid Profile in a Cystic Fibrosis Cell Line.

Authors:  Michele Dei Cas; Aida Zulueta; Alessandra Mingione; Anna Caretti; Riccardo Ghidoni; Paola Signorelli; Rita Paroni
Journal:  Cells       Date:  2020-05-12       Impact factor: 6.600

2.  Sphingolipids and plasma membrane hydrolases in human primary bronchial cells during differentiation and their altered patterns in cystic fibrosis.

Authors:  Nicoletta Loberto; Giulia Mancini; Rosaria Bassi; Emma Veronica Carsana; Anna Tamanini; Nicoletta Pedemonte; Maria Cristina Dechecchi; Sandro Sonnino; Massimo Aureli
Journal:  Glycoconj J       Date:  2020-07-14       Impact factor: 2.916

Review 3.  PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases.

Authors:  Márcia V de Carvalho; Cassiano F Gonçalves-de-Albuquerque; Adriana R Silva
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

Review 4.  Cystic Fibrosis Lung Disease in the Aging Population.

Authors:  Lisa Künzi; Molly Easter; Meghan June Hirsch; Stefanie Krick
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

5.  The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors.

Authors:  Ignazio G Vetrano; Michele Dei Cas; Vittoria Nazzi; Marica Eoli; Niccolò Innocenti; Veronica Saletti; Antonella Potenza; Tatiana Carrozzini; Giuliana Pollaci; Gemma Gorla; Rita Paroni; Riccardo Ghidoni; Laura Gatti
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

6.  Link between serum lipid signature and prognostic factors in COVID-19 patients.

Authors:  Michele Dei Cas; Sara Ottolenghi; Camillo Morano; Rocco Rinaldo; Gabriella Roda; Davide Chiumello; Stefano Centanni; Michele Samaja; Rita Paroni
Journal:  Sci Rep       Date:  2021-11-04       Impact factor: 4.379

7.  Cystic Fibrosis Defective Response to Infection Involves Autophagy and Lipid Metabolism.

Authors:  Alessandra Mingione; Emerenziana Ottaviano; Matteo Barcella; Ivan Merelli; Lorenzo Rosso; Tatiana Armeni; Natalia Cirilli; Riccardo Ghidoni; Elisa Borghi; Paola Signorelli
Journal:  Cells       Date:  2020-08-06       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.